PKMYT1 and chronic myelogenous leukemia, BCR-ABL1 positive: Our findings not only elucidate the mechanism by which Mei exerts its antitumor effects but also provide a blueprint for the development of molecular glue‐based therapeutics targeting PKMYT1, offering new avenues for the treatment of CML and potentially other cancers.